Clinical Trials Browser

Neoplasms

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06735820 2025-07-03

MEKMDM2

Phase 1/2 Not yet recruiting

45 enrolled

CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

NCT03326388 2024-04-04

INSPECT

Phase 1/2 Completed

14 enrolled

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform, Optic Nerve Glioma

NCT03705507 2023-05-11

SeluDex

Phase 1/2 Terminated

12 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02583542 2020-02-25

TORCMEK

Phase 1/2 Unknown

118 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01752569 2019-02-20

SCART

Phase 1/2 Terminated

19 enrolled

Sarcoma

AIDS-related Kaposi sarcoma, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT02450656 2018-08-27

M14AFS

Phase 1/2 Unknown

320 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02025114 2018-07-10

Selumetinib in Combination With Gefitinib in NSCLC Patients

Phase 1/2 Completed

34 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01029418 2015-04-16

AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma

Phase 1/2 Terminated

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Clinical Trials

ESMART

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

MEKMDM2

INSPECT

SeluDex

TORCMEK

SCART

M14AFS

Selumetinib in Combination With Gefitinib in NSCLC Patients

AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma